ARTICLE | Preclinical News

Resolvins keep tumor debris from stimulating tumor growth

November 30, 2017 11:28 PM UTC

In an article published in the Journal of Experimental Medicine, researchers at Beth Israel Deaconess Medical Center and colleagues showed that resolvins, a class of lipids, can suppress the pro-cancer activity of tumor debris generated by cancer therapies by activating macrophage clearance of debris.

Dipak Panigrahy, an assistant professor of pathology at Beth Israel who led the study, told BioCentury that debris-driven tumor growth could explain some adverse therapy responses and resolvins could be a solution...